The DOI matches its Crossref record; 123 of the 123 references it cites were found in a registry or an index.
TP53 Mutations in Human Cancer: Database Reassessment and Prospects for the Next Decade
Open accessAbstract
More than 50% of human tumors carry TP53 gene mutations and in consequence more than 45,000 somatic and germline mutations have been gathered in the UMD TP53 database (http://p53.fr). Analyses of these mutations have been invaluable for bettering our knowledge on the structure-function relationships within the TP53 protein and the high degree of heterogeneity of the various TP53 mutants in human cancer. In this review, we discuss how with the release of the sequences of thousands of tumor genomes issued from high-throughput sequencing, the description of novel TP53 mutants is now reaching a plateau indicating that we are close to the full set of mutants that target the elusive tumor-suppressive activity of this protein. We performed an extensive and thorough analysis of the TP53 mutation database, focusing particularly on specific sets of mutations that were overlooked in the past because of their low frequencies, for example, synonymous mutations, splice mutations, or mutations-targeting residues subject to posttranslational modifications. We also discuss the evolution of the statistical methods used to differentiate TP53 passenger mutations and artifactual data from true mutations, a process vital to the release of an accurate TP53 mutation database that will in turn be an invaluable tool for both clinicians and researchers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
METABRIC Group, Curtis, C., Shah, S. P., Chin, S.-F., Turashvili, G., Rueda, O. M., Dunning, M. J., Speed, D., Lynch, A. G., Samarajiwa, S., et al. (2012) · Nature · doi:10.1038/nature10983 · Cited by 6,097
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Mutational landscape and significance across 12 major cancer types
Kandoth, C., McLellan, M. D., Vandin, F., Ye, K., Niu, B., Lu, C., Xie, M., Zhang, Q., McMichael, J. F., Wyczalkowski, M. A., et al. (2013) · Nature · doi:10.1038/nature12634 · Cited by 4,419
The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53
Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J., & Howley, P. M. (1990) · Cell · doi:10.1016/0092-8674(90)90409-8 · Cited by 3,995
Stratton, M. R., Campbell, P. J., & Futreal, P. A. (2009) · Nature · doi:10.1038/nature07943 · Cited by 3,449
Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994) · Science · doi:10.1126/science.8023157 · Cited by 2,551
T antigen is bound to a host protein in SY40-transformed cells
LANE, D. P., & CRAWFORD, L. V. (1979) · Nature · doi:10.1038/278261a0 · Cited by 2,394
Vousden, K. H., & Lane, D. P. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2147 · Cited by 2,272
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
Dawson, S.-J., Tsui, D. W. Y., Murtaza, M., Biggs, H., Rueda, O. M., Chin, S.-F., Dunning, M. J., Gale, D., Forshew, T., Mahler-Araujo, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213261 · Cited by 2,207
Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain
Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206
Chromosome 17 Deletions and p53 Gene Mutations in Colorectal Carcinomas
Baker, S. J., Fearon, E. R., Nigro, J. M., Hamilton, S. R., Preisinger, A. C., Jessup, J. M., vanTuinen, P., Ledbetter, D. H., Barker, D. F., Nakamura, Y., et al. (1989) · Science · doi:10.1126/science.2649981 · Cited by 2,066
Predicting the functional impact of protein mutations: application to cancer genomics
Reva, B., Antipin, Y., & Sander, C. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr407 · Cited by 2,002
Linzer, D. I. H., & Levine, A. J. (1979) · Cell · doi:10.1016/0092-8674(79)90293-9 · Cited by 1,813
Human papillomavirus oncoproteins: pathways to transformation
Moody, C. A., & Laimins, L. A. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2886 · Cited by 1,751
Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53
Oliner, J. D., Pietenpol, J. A., Thiagalingam, S., Gyuris, J., Kinzler, K. W., & Vogelstein, B. (1993) · Nature · doi:10.1038/362857a0 · Cited by 1,451
MDM2, MDMX and p53 in oncogenesis and cancer therapy
Wade, M., Li, Y.-C., & Wahl, G. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3430 · Cited by 1,279
Deciphering Signatures of Mutational Processes Operative in Human Cancer
Alexandrov, L. B., Nik-Zainal, S., Wedge, D. C., Campbell, P. J., & Stratton, M. R. (2013) · Cell Reports · doi:10.1016/j.celrep.2012.12.008 · Cited by 1,277
p53: A Frequent Target for Genetic Abnormalities in Lung Cancer
Takahashi, T., Nau, M. M., Chiba, I., Birrer, M. J., Rosenberg, R. K., Vinocour, M., Levitt, M., Pass, H., Gazdar, A. F., & Minna, J. D. (1989) · Science · doi:10.1126/science.2554494 · Cited by 1,197
Detection and quantification of mutations in the plasma of patients with colorectal tumors
Diehl, F., Li, M., Dressman, D., He, Y., Shen, D., Szabo, S., Diaz, L. A., Goodman, S. N., David, K. A., Juhl, H., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507904102 · Cited by 1,188
An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers
Roberts, S. A., Lawrence, M. S., Klimczak, L. J., Grimm, S. A., Fargo, D., Stojanov, P., Kiezun, A., Kryukov, G. V., Carter, S. L., Saksena, G., et al. (2013) · Nature Genetics · doi:10.1038/ng.2702 · Cited by 1,167
A small-cell lung cancer genome with complex signatures of tobacco exposure
Pleasance, E. D., Stephens, P. J., O’Meara, S., McBride, D. J., Meynert, A., Jones, D., Lin, M.-L., Beare, D., Lau, K. W., Greenman, C., et al. (2010) · Nature · doi:10.1038/nature08629 · Cited by 1,066
Splicing in disease: disruption of the splicing code and the decoding machinery
Wang, G.-S., & Cooper, T. A. (2007) · Nature Reviews Genetics · doi:10.1038/nrg2164 · Cited by 1,050
Understanding the contribution of synonymous mutations to human disease
Sauna, Z. E., & Kimchi-Sarfaty, C. (2011) · Nature Reviews Genetics · doi:10.1038/nrg3051 · Cited by 1,022
Predicting the Effects of Amino Acid Substitutions on Protein Function
Ng, P. C., & Henikoff, S. (2006) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.7.080505.115630 · Cited by 978
The CpG dinucleotide and human genetic disease
Cooper, D. N., & Youssoufian, H. (1988) · Human Genetics · doi:10.1007/bf00278187 · Cited by 931
Tumor Suppression in the Absence of p53-Mediated Cell-Cycle Arrest, Apoptosis, and Senescence
Li, T., Kon, N., Jiang, L., Tan, M., Ludwig, T., Zhao, Y., Baer, R., & Gu, W. (2012) · Cell · doi:10.1016/j.cell.2012.04.026 · Cited by 912
Kato, S., Han, S.-Y., Liu, W., Otsuka, K., Shibata, H., Kanamaru, R., & Ishioka, C. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1431692100 · Cited by 874
APOBEC3B is an enzymatic source of mutation in breast cancer
Burns, M. B., Lackey, L., Carpenter, M. A., Rathore, A., Land, A. M., Leonard, B., Refsland, E. W., Kotandeniya, D., Tretyakova, N., Nikas, J. B., et al. (2013) · Nature · doi:10.1038/nature11881 · Cited by 838
Stommel, J. M., Marchenko, N. D., Jimenez, G. S., Moll, U. M., Hope, T. J., & Wahl, G. M. (1999) · The EMBO Journal · doi:10.1093/emboj/18.6.1660 · Cited by 738
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy
Barretina, J., Taylor, B. S., Banerji, S., Ramos, A. H., Lagos-Quintana, M., DeCarolis, P. L., Shah, K., Socci, N. D., Weir, B. A., Ho, A., et al. (2010) · Nature Genetics · doi:10.1038/ng.619 · Cited by 735
Exploring the Genomes of Cancer Cells: Progress and Promise
Stratton, M. R. (2011) · Science · doi:10.1126/science.1204040 · Cited by 693
Mutual exclusivity analysis identifies oncogenic network modules
Ciriello, G., Cerami, E., Sander, C., & Schultz, N. (2012) · Genome Research · doi:10.1101/gr.125567.111 · Cited by 675
Assessing TP53 status in human tumours to evaluate clinical outcome
Soussi, T., & Béroud, C. (2001) · Nature reviews. Cancer · doi:10.1038/35106009 · Cited by 659
Self-citationHussain, S. P., Schwank, J., Staib, F., Wang, X. W., & Harris, C. C. (2007) · Oncogene · doi:10.1038/sj.onc.1210279 · Cited by 621
Aristolochic acid and the etiology of endemic (Balkan) nephropathy
Grollman, A. P., Shibutani, S., Moriya, M., Miller, F., Wu, L., Moll, U., Suzuki, N., Fernandes, A., Rosenquist, T., Medverec, Z., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701248104 · Cited by 606
Inactivation of the p53 pathway in retinoblastoma
Laurie, N. A., Donovan, S. L., Shih, C.-S., Zhang, J., Mills, N., Fuller, C., Teunisse, A., Lam, S., Ramos, Y., Mohan, A., et al. (2006) · Nature · doi:10.1038/nature05194 · Cited by 595
TP53 tumor suppressor gene: A model for investigating human mutagenesis
Fromentel, C. C. D., & Soussi, T. (1992) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.2870040102 · Cited by 574
Self-citationHistological types of breast cancer: How special are they?
Weigelt, B., Geyer, F. C., & Reis-Filho, J. S. (2010) · Molecular Oncology · doi:10.1016/j.molonc.2010.04.004 · Cited by 572
Synonymous Mutations Frequently Act as Driver Mutations in Human Cancers
Supek, F., Miñana, B., Valcárcel, J., Gabaldón, T., & Lehner, B. (2014) · Cell · doi:10.1016/j.cell.2014.01.051 · Cited by 557
microRNAs join the p53 network — another piece in the tumour-suppression puzzle
He, L., He, X., Lowe, S. W., & Hannon, G. J. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2232 · Cited by 547
Ribeiro, R. C., Sandrini, F., Figueiredo, B., Zambetti, G. P., Michalkiewicz, E., Lafferty, A. R., DeLacerda, L., Rabin, M., Cadwell, C., Sampaio, G., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.161479898 · Cited by 541
Distinct p53 Transcriptional Programs Dictate Acute DNA-Damage Responses and Tumor Suppression
Brady, C. A., Jiang, D., Mello, S. S., Johnson, T. M., Jarvis, L. A., Kozak, M. M., Broz, D. K., Basak, S., Park, E. J., McLaughlin, M. E., et al. (2011) · Cell · doi:10.1016/j.cell.2011.03.035 · Cited by 533
MicroRNAs in the p53 network: micromanagement of tumour suppression
Hermeking, H. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3318 · Cited by 518 · cited 2×
“target genes including BBC3 (PUMA), CCNC, CDC25A, or BAK1 [Hermeking, 2012].”
A Genomics-Based Classification of Human Lung Tumors
The Clinical Lung Cancer Genome Project (CLCGP) and Network Genomic Medicine (NGM) (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006802 · Cited by 511
Posttranslational Modification of p53: Cooperative Integrators of Function
Meek, D. W., & Anderson, C. W. (2009) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000950 · Cited by 483
Rearrangement of the p53 gene in human osteogenic sarcomas.
Masuda, H., Miller, C., Koeffler, H. P., Battifora, H., & Cline, M. J. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.21.7716 · Cited by 474
Rodenhuis, S., Slebos, R. J. C., Boot, A. J., Evers, S. G., Mooi, W. J., WAGENAAR, S. S., Bodegom, P. C. V., & Bos, J. L. (1988) · PubMed · Cited by 465
p53 mutation in hepatocellular carcinoma after aflatoxin exposure
Bressac, B., Puisieux, A., Kew, M., Volkmann, M., Bozcall, S., Bella Mura, J., de la Monte, S., Carlson, R., Blum, H., Wands, J., et al. (1991) · The Lancet · doi:10.1016/0140-6736(91)92236-u · Cited by 449
Metabolic Regulation by p53 Family Members
Berkers, C. R., Maddocks, O. D. K., Cheung, E. C., Mor, I., & Vousden, K. H. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.06.019 · Cited by 446
Blandino, G., Levine, A. J., & Oren, M. (1999) · Oncogene · doi:10.1038/sj.onc.1202314 · Cited by 441
Lehmann, S., Bykov, V. J. N., Ali, D., Andrén, O., Cherif, H., Tidefelt, U., Uggla, B., Yachnin, J., Juliusson, G., Moshfegh, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.7783 · Cited by 406 · cited 1×
“In the wake of the disappointment surrounding gene and viral therapies, a new generation of chemical drugs targeting mutant TP53 is under development and several candidates are currently in clinical trials [Lehmann et al., 2012].”
BackgroundKress, M., May, E., Cassingena, R., & May, P. (1979) · Journal of Virology · doi:10.1128/jvi.31.2.472-483.1979 · Cited by 359
Cytosine methylation determines hot spots of DNA damage in the human P 53 gene
Denissenko, M. F., Chen, J. X., Tang, M.-S., & Pfeifer, G. P. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.8.3893 · Cited by 339
Making sense of cancer genomic data
Chin, L., Hahn, W. C., Getz, G., & Meyerson, M. (2011) · Genes & Development · doi:10.1101/gad.2017311 · Cited by 336
Regulatory Mechanisms of Tumor Suppressor P16INK4Aand Their Relevance to Cancer
Li, J., Poi, M. J., & Tsai, M.-D. (2011) · Biochemistry · doi:10.1021/bi200642e · Cited by 334
High-Resolution Structure of the Oligomerization Domain of p53 by Multidimensional NMR
Clore, G. M., Omichinski, J. G., Sakaguchi, K., Zambrano, N., Sakamoto, H., Appella, E., & Gronenborn, A. M. (1994) · Science · doi:10.1126/science.8023159 · Cited by 307
Sunlight and the onset of skin cancer
Brash, D. E. (1997) · Trends in Genetics · doi:10.1016/s0168-9525(97)01246-8 · Cited by 305
Molecular biology of lung cancer.
Cooper, W. A., Lam, D. C.-L., O'Toole, S. A., & Minna, J. D. (2013) · PubMed · doi:10.3978/j.issn.2072-1439.2013.08.03 · Cited by 303
A novel mechanism of tumorigenesis involving pH-dependent destabilization of a mutant p53 tetramer
DiGiammarino, E. L., Lee, A. S., Cadwell, C., Zhang, W., Bothner, B., Ribeiro, R. C., Zambetti, G., & Kriwacki, R. W. (2002) · Nature Structural Biology · doi:10.1038/nsb730 · Cited by 294
TP53 mutations in human skin cancers
Giglia-Mari, G., & Sarasin, A. (2003) · Human Mutation · doi:10.1002/humu.10179 · Cited by 292
Valente, L. J., Gray, D. H. D., Michalak, E. M., Pinon-Hofbauer, J., Egle, A., Scott, C. L., Janic, A., & Strasser, A. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.04.012 · Cited by 291
Genome-Wide Mutational Signatures of Aristolochic Acid and Its Application as a Screening Tool
Poon, S. L., Pang, S.-T., McPherson, J. R., Yu, W., Huang, K. K., Guan, P., Weng, W.-H., Siew, E. Y., Liu, Y., Heng, H. L., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006086 · Cited by 289
Mutational Signature of Aristolochic Acid Exposure as Revealed by Whole-Exome Sequencing
Hoang, M. L., Chen, C.-H., Sidorenko, V. S., He, J., Dickman, K. G., Yun, B. H., Moriya, M., Niknafs, N., Douville, C., Karchin, R., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006200 · Cited by 284
GATA Transcription Factors and Cancer
Zheng, R., & Blobel, G. A. (2010) · Genes & Cancer · doi:10.1177/1947601911404223 · Cited by 276
TheTP53 gene, tobacco exposure, and lung cancer
Toyooka, S., Tsuda, T., & Gazdar, A. F. (2003) · Human Mutation · doi:10.1002/humu.10177 · Cited by 276
Small-Molecule Antagonists of p53-MDM2 Binding: Research Tools and Potential Therapeutics
Vassilev, L. T. (2004) · Cell Cycle · doi:10.4161/cc.3.4.801 · Cited by 271
The p53 family: guardians of maternal reproduction
Levine, A. J., Tomasini, R., McKeon, F. D., Mak, T. W., & Melino, G. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3086 · Cited by 252
Molecular Biology of Lung Cancer
Nana-Sinkam, S. P., & Powell, C. A. (2013) · Chest · doi:10.1378/chest.12-2346 · Cited by 248
Tornaletti, S., & Pfeifer, G. P. (1995) · PubMed · Cited by 247
Lane, D. P., Cheok, C. F., & Lain, S. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001222 · Cited by 246
Targeting Tumor Suppressor p53 for Cancer Therapy: Strategies, Challenges and Opportunities
Hong, B., Heuvel, A., Prabhu, V., Zhang, S., & El-Deiry, W. (2014) · Current Drug Targets · doi:10.2174/1389450114666140106101412 · Cited by 245
Staib, F., Perwez Hussain, S., Hofseth, L. J., Wang, X. W., & Harris, C. C. (2003) · Human Mutation · doi:10.1002/humu.10176 · Cited by 241
Analysis of TP53 Mutation Status in Human Cancer Cell Lines: A Reassessment
Leroy, B., Girard, L., Hollestelle, A., Minna, J. D., Gazdar, A. F., & Soussi, T. (2014) · Human Mutation · doi:10.1002/humu.22556 · Cited by 224
Self-citationRefined solution structure of the oligomerization domain of the tumour suppressor p53
Clore, G. M., Ernst, J., Clubb, R., Omichinski, J. G., Kennedy, W. M. P., Sakaguchi, K., Appella, E., & Gronenborn, A. M. (1995) · Nature Structural & Molecular Biology · doi:10.1038/nsb0495-321 · Cited by 222
Levine, A. J. (2009) · Virology · doi:10.1016/j.virol.2008.09.034 · Cited by 212
Custódio, G., Parise, G. A., Kiesel Filho, N., Komechen, H., Sabbaga, C. C., Rosati, R., Grisa, L., Parise, I. Z. S., Pianovski, M. A. D., Fiori, C. M. C. M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.3711 · Cited by 201
Olsson, A., Manzl, C., Strasser, A., & Villunger, A. (2007) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402196 · Cited by 200
Clinical significance of p53 alterations in surgically treated prostate cancers
Schlomm, T., Iwers, L., Kirstein, P., Jessen, B., Köllermann, J., Minner, S., Passow-Drolet, A., Mirlacher, M., Milde-Langosch, K., Graefen, M., et al. (2008) · Modern Pathology · doi:10.1038/modpathol.2008.104 · Cited by 196
The Isoforms of the p53 Protein
Khoury, M. P., & Bourdon, J.-C. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000927 · Cited by 191
GermlineTP53Mutations and the Changing Landscape of Li-Fraumeni Syndrome
Kamihara, J., Rana, H. Q., & Garber, J. E. (2014) · Human Mutation · doi:10.1002/humu.22559 · Cited by 182
Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies
Xu-Monette, Z. Y., Medeiros, L. J., Li, Y., Orlowski, R. Z., Andreeff, M., Bueso-Ramos, C. E., Greiner, T. C., McDonnell, T. J., & Young, K. H. (2012) · Blood · doi:10.1182/blood-2011-11-366062 · Cited by 179
How many molecular subtypes? Implications of the unique tumor principle in personalized medicine
Ogino, S., Fuchs, C. S., & Giovannucci, E. (2012) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.12.46 · Cited by 177
Ory, K., Legros, Y., Auguin, C., & Soussi, T. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06656.x · Cited by 163
Self-citationLocus-specific mutation databases: pitfalls and good practice based on the p53 experience
Soussi, T., Ishioka, C., Claustres, M., & Béroud, C. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1783 · Cited by 144
Self-citationDistinct tumor protein p53 mutants in breast cancer subgroups
Dumay, A., Feugeas, J., Evelyne, W.-D., Lehmann‐Che, J., Bertheau, P., Espié, M., Plassa, L., Cottu, P. H., Marty, M. E., André, F., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.27767 · Cited by 142
The molecular epidemiology of P53 gene mutations in human breast cancer
Hartmann, A., Blaszyk, H., Kovach, J. S., & Sommer, S. S. (1997) · Trends in Genetics · doi:10.1016/s0168-9525(96)10043-3 · Cited by 139
Soussi, T., Kato, S., Lévy, P., & Ishioka, C. (2004) · Human Mutation · doi:10.1002/humu.20114 · Cited by 139
Self-citationActivation and control of p53 tetramerization in individual living cells
Gaglia, G., Guan, Y., Shah, J. V., & Lahav, G. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1311126110 · Cited by 135
Increased apoptosis induction by 121F mutant p53
Saller, E., Tom, E., Brunori, M., Otter, M., Estreicher, A., Mack, D. H., & Iggo, R. D. (1999) · The EMBO Journal · doi:10.1093/emboj/18.16.4424 · Cited by 130
Kawaguchi, T., Kato, S., Otsuka, K., Watanabe, G., Kumabe, T., Tominaga, T., Yoshimoto, T., & Ishioka, C. (2005) · Oncogene · doi:10.1038/sj.onc.1208839 · Cited by 128
Berglind, H., Yudi Pawitan, Y., Kato, S., Ishioka, C., & Soussi, T. (2008) · Cancer Biology & Therapy · doi:10.4161/cbt.7.5.5712 · Cited by 116
Self-citationRajagopalan, S., Huang, F., & Fersht, A. R. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq800 · Cited by 112
Aylon, Y., & Oren, M. (2011) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2010.10.002 · Cited by 106 · cited 1×
“However, several recent reviews are available [Aylon and Oren, 2011; Levine et al., 2011; Berkers et al., 2013].”
BackgroundYou, Y.-H., Szabó, P. E., & Pfeifer, G. P. (2000) · Carcinogenesis · doi:10.1093/carcin/21.11.2113 · Cited by 103
Soussi, T., & Béroud, C. (2003) · Human Mutation · doi:10.1002/humu.10189 · Cited by 103
Self-citationTherapeutic targeting of p53 by small molecules
Selivanova, G. (2010) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2010.02.006 · Cited by 93
Edlund, K., Larsson, O. S., Ameur, A., Bunikis, I., Gyllensten, U. B., Leroy, B., Sundström, M., Micke, P., Botling, J., & Soussi, T. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1200019109 · Cited by 90
Self-citationTP53 Mutations in Human Cancer: Database Reassessment and Prospects for the Next Decade
Soussi, T. (2011) · Advances in cancer research · doi:10.1016/b978-0-12-386469-7.00005-0 · Cited by 86
Self-citationCancer-associated p53 Tetramerization Domain Mutants
Kamada, R., Nomura, T., Anderson, C. W., & Sakaguchi, K. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.174698 · Cited by 82
Soussi, T., Asselain, B. J. R., Hamroun, D., Kato, S., Ishioka, C., Claustres, M., & Béroud, C. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0413 · Cited by 80
Self-citationRescue of the apoptotic-inducing function of mutant p53 by small molecule RITA
Zhao, C. Y., Grinkevich, V., Nikulenkov, F., Bao, W., & Selivanova, G. (2010) · Cell Cycle · doi:10.4161/cc.9.9.11545 · Cited by 79
Mutant TP53 Posttranslational Modifications: Challenges and Opportunities
Nguyen, T.-A., Menendez, D., Resnick, M. A., & Anderson, C. W. (2014) · Human Mutation · doi:10.1002/humu.22506 · Cited by 69
Fraud and misconduct in clinical research: A concern
Gupta, A. (2013) · Perspectives in Clinical Research · doi:10.4103/2229-3485.111800 · Cited by 67
Ultraslow oligomerization equilibria of p53 and its implications
Natan, E., Hirschberg, D., Morgner, N., Robinson, C. V., & Fersht, A. R. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0907840106 · Cited by 56
Letouzé, É., Rosati, R., Komechen, H., Doghman, M., Marisa, L., Flück, C. E., de Krijger, R. R., van Noesel, M. M., Mas, J.-C., Pianovski, M. A. D., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1184 · Cited by 56
Mutational Analysis of the p53 Core Domain L1 Loop
Zupnick, A., & Prives, C. L. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m603387200 · Cited by 52
Genetic and functional studies of a germline TP53 splicing mutation in a Li–Fraumeni-like family
Varley, J. M., Chapman, P. J., McGown, G., Thorncroft, M. R., White, G. R. M., Greaves, M. J., Scott, D., Spreadborough, A. R., Tricker, K. J., Birch, J. M., et al. (1998) · Oncogene · doi:10.1038/sj.onc.1201878 · Cited by 52
Slade, N., Moll, U. M., Brdar, B., Zorić, A., & Jelaković, B. (2009) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2009.01.005 · Cited by 50
Biomarkers in cancer epidemiology: an integrative approach
Boffetta, P. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp269 · Cited by 45
Recommendations for Analyzing and ReportingTP53Gene Variants in the High-Throughput Sequencing Era
Soussi, T., Leroy, B., & Taschner, P. E. M. (2014) · Human Mutation · doi:10.1002/humu.22561 · Cited by 40
Self-citationExon sequences at the splice junctions affect splicing fidelity and alternative splicing
Crotti, L. B., & Horowitz, D. S. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0907948106 · Cited by 38
TP53 Mutation Analysis in Clinical Practice: Lessons From Chronic Lymphocytic Leukemia
Malčíková, J., Pavlová, Š., Kozubík, K. S., & Pospíšilová, Š. (2014) · Human Mutation · doi:10.1002/humu.22508 · Cited by 33
Insights into Wild-Type and Mutant p53 Functions Provided by Genetically Engineered Mice
Donehower, L. A. (2014) · Human Mutation · doi:10.1002/humu.22507 · Cited by 33
Soussi, T. (2011) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2011.07.003 · Cited by 21
Self-citationp53 Protein Isoforms: Key Regulators in the Front Line of Pathogen Infections?
Terrier, O., Bourdon, J., & Rosa‐Calatrava, M. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003246 · Cited by 19
Locus-Specific Databases in Cancer: What Future in a Post-Genomic Era? The TP53 LSDB paradigm
Soussi, T. (2014) · Human Mutation · doi:10.1002/humu.22518 · Cited by 17
Self-citationTumor suppressor p53 ( TP53 ) at the crossroads of the exposome and the cancer genome
Schetter, A. J., & Harris, C. C. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1205457109 · Cited by 12
Cited by
Daly, M. B., Pal, T., Berry, M. P., Buys, S. S., Dickson, P., Domchek, S. M., Elkhanany, A., Friedman, S., Goggins, M., Hutton, M. L., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0001 · Cited by 1,112
Targeting mutant p53 for efficient cancer therapy
Bykov, V. J. N., Eriksson, S. E., Bianchi, J., & Wiman, K. G. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.109 · Cited by 889
Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas
Donehower, L. A., Soussi, T., Korkut, A., Liu, Y., Schultz, A., Cardenas, M., Li, X., Babur, O., Hsu, T.-K., Lichtarge, O., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.07.001 · Cited by 710
Self-citationThe p53 Pathway: Origins, Inactivation in Cancer, and Emerging Therapeutic Approaches
Joerger, A. C., & Fersht, A. R. (2016) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060815-014710 · Cited by 661
Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer
Hong, M. K. H., Macintyre, G., Wedge, D. C., Van Loo, P., Patel, K., Lunke, S., Alexandrov, L. B., Sloggett, C., Cmero, M., Marass, F., et al. (2015) · Nature Communications · doi:10.1038/ncomms7605 · Cited by 372
Metadata
- Authors
- Leroy, B., Anderson, M., & Soussi, T.
- Venue
- Human Mutation
- Publisher
- Hindawi Limited
- Published
- 2014-05-20
- Volume
- 35
- Issue
- 6
- Pages
- 672-688
- ISSN
- 1059-7794 (ISSN-L)
- OpenAlex
- W2110523744
- Cited by
- 408
- References
- 123
- FWCI
- 10.34
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.